Poniard Pharmaceuticals Probability of Future Pink Sheet Price Finishing Under 0.0085
| PARDDelisted Stock | USD 0.01 0.00 0.00% |
Poniard |
Poniard Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Poniard Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Poniard Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Poniard Pharmaceuticals is not yet fully synchronised with the market data | |
| Poniard Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Poniard Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Poniard Pharmaceuticals currently holds 1.57 M in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Poniard Pharmaceuticals has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Poniard Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Poniard Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Poniard Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Poniard to invest in growth at high rates of return. When we think about Poniard Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (30.05 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Poniard Pharmaceuticals currently holds about 1.98 M in cash with (24.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Poniard Pharmaceuticals Technical Analysis
Poniard Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Poniard Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Poniard Pharmaceuticals. In general, you should focus on analyzing Poniard Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Poniard Pharmaceuticals Predictive Forecast Models
Poniard Pharmaceuticals' time-series forecasting models is one of many Poniard Pharmaceuticals' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Poniard Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Poniard Pharmaceuticals
Checking the ongoing alerts about Poniard Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Poniard Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Poniard Pharmaceuticals is not yet fully synchronised with the market data | |
| Poniard Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Poniard Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Poniard Pharmaceuticals currently holds 1.57 M in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Poniard Pharmaceuticals has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Poniard Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Poniard Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Poniard Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Poniard to invest in growth at high rates of return. When we think about Poniard Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (30.05 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Poniard Pharmaceuticals currently holds about 1.98 M in cash with (24.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Poniard Pink Sheet
If you are still planning to invest in Poniard Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Poniard Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |